| Beck
EJ, Gaudreault M, Brewer CG, Mandalia S, Zowall
H, Gilmore N, Klein M, Lalonde R, Murphy T, Piche, A, Platt R, Roy
J, de la Sablonniere, Hankins C. Cost-effectiveness of HAART in
Quebec , 1991-2001. Canadian Association for HIV Research (CAHR),
Thirteen’s Annual Canadian Conference on HIV/AIDS Research,
13-16 May, 2004, Montreal, Quebec.
Grover
SA, Zowall H, Brewer CG, Gilmore, Mukherjee J.
Highly active antiretroviral therapy (HAART) for HIV infections
and dyslipidemia : Estimating the impact of nelfinavir and atazanavir
on cardiovascular (CVD) risk and life expectancy (LE) after adjustment
for HIV related mortality. 4th Scientific Forum on Quality of Care
and Outcomes Research in Cardiovascular Disease and Stroke, October
13-14, 2002, Washington, D.C.
Grover
SA, Brewer CG, Coupal L, Zowall H, Pradhan A. Estimating
the benefits of
Antihypertensive therapy: an assessment of pressure. International
Society for
Pharmacoeconomics & Outcomes Research, (ISPOR), Seventh Annual
International Meeting, 19-22 May 2002, Crystal City, Arlington,
VA. |
